Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;76(1 Suppl 1):1S47-52.
doi: 10.1016/S0003-4266(16)30014-2.

Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer

C Do Cao  1 , J-L Wémeau  2
Affiliations

Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer

C Do Cao et al. Ann Endocrinol (Paris). 2015 Feb.

Abstract

In the setting of differentiated thyroid cancer (DTC) management, < 0.1 mU/L TSH suppression has been proven to be beneficial for patients likely to have microscopic or macroscopic disease, as TSH has a direct trophic effect on thyroid cancer cells. However, the optimal degree of TSH reduction remains unclear for other categories of DTC patients with better prognosis. Excessive thyroid hormone replacement can lead to atrial fibrillation and osteoporosis. Therefore, levothyroxine dose should be carefully adjusted with respect to underlying individual health status, dynamically reassessed risk of relapse and medical monitoring. Future guidelines should give priority to a tailored approach to TSH suppression therapy in DTC patients.

Keywords: Adverse effects; Cancer thyroïdien; Effets secondaires; Frénateur; Levothyroxine; Suppressive; TSH; Therapy; Thyroid cancer; Traitement.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles